Kivu Bioscience raised $92 million in a Series A led by Novo Holdings to advance multiple oncology programs into the clinic.
Amount Raised
$92 Million
Round Type
Series A
San FranciscoBiotechnologyHealth CareInvestors
Description
Kivu Bioscience has successfully closed a $92 million Series A financing round, led by Novo Holdings alongside various other investors. The funds will be utilized to push their next-generation antibody-drug conjugates into clinical development, aiming for safer and more effective cancer treatments.
Quick answer
Kivu Bioscience raised $92 Million in a Series A round, dated October 28, 2024. Investors: Healthcap, BioGeneration Ventures, Gimv, Red Tree Venture Capital, M Ventures, Brabantse Ontwikkelings Maatschappij (Bom) and Novo Holdings. Kivu Bioscience is based in San Francisco, California, United States.
- How much did Kivu Bioscience raise?
- Kivu Bioscience raised $92 Million in a Series A round on October 28, 2024.
- Who invested in Kivu Bioscience?
- Healthcap, BioGeneration Ventures, Gimv, Red Tree Venture Capital, M Ventures, Brabantse Ontwikkelings Maatschappij (Bom) and Novo Holdings are named as investors in this round.
- What does Kivu Bioscience do?
- Kivu Bioscience is pioneering next-generation antibody-drug conjugates (ADCs) in oncology.
- Where is Kivu Bioscience based and how big is it?
- Kivu Bioscience is based in San Francisco, California, United States.
- Who are the decision-makers at Kivu Bioscience?
- Fundz holds 2 contacts at Kivu Bioscience. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Kivu Bioscience that raised within 45 days of this round, from Fundz verified event records.
- Pleno raised $25M (Series B) on December 12, 2024.
- Parol raised $1.3M (Seed) on December 12, 2024.
- LaNua Medical raised $6.3M (Seed) on December 12, 2024.
- Syncell raised $15M (Series A) on December 11, 2024.
- Noema Pharma raised $147M (Series B) on December 11, 2024.
- East Ocyon Bio raised $4.2M (Seed) on December 11, 2024.
Who to call at Kivu Bioscience, and when
A new round usually means Kivu Bioscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kivu Bioscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kivu Bioscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kivu Bioscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kivu Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansKivu Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.